Back to top

Advisory Board (ABCO) in Focus: Stock Moves 6.4% Higher
August 30, 2017

Read MoreHide Full Article

The Advisory Board Company (ABCO - Free Report) was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 5.6% in the past one-month time frame.

The stock gained after the company reported that it reached a $2.58 billion deal to sell its education and health care businesses.

The company has seen a mixed track record when it comes to estimate revisions of four increases and five decreases over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Advisory Board currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

A better-ranked stock in the Medical Services industry is BioTelemetry, Inc. (BEAT - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ABCO going up? Or down? Predict to see what others think: Up or Down

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.

See Stocks Now>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioTelemetry, Inc. (BEAT) - free report >>

The Advisory Board Company (ABCO) - free report >>


More from Zacks Tale of the Tape

You May Like